GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » COGS-to-Revenue

PositiveID (PositiveID) COGS-to-Revenue : 0.54 (As of Mar. 2018)


View and export this data going back to 2007. Start your Free Trial

What is PositiveID COGS-to-Revenue?

PositiveID's Cost of Goods Sold for the three months ended in Mar. 2018 was $0.23 Mil. Its Revenue for the three months ended in Mar. 2018 was $0.42 Mil.

PositiveID's COGS to Revenue for the three months ended in Mar. 2018 was 0.54.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PositiveID's Gross Margin % for the three months ended in Mar. 2018 was 45.71%.


PositiveID COGS-to-Revenue Historical Data

The historical data trend for PositiveID's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID COGS-to-Revenue Chart

PositiveID Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.31 0.11 0.64 0.66

PositiveID Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.61 0.64 0.71 0.54

PositiveID COGS-to-Revenue Calculation

PositiveID's COGS to Revenue for the fiscal year that ended in Dec. 2017 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.514 / 5.359
=0.66

PositiveID's COGS to Revenue for the quarter that ended in Mar. 2018 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.228 / 0.42
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PositiveID  (OTCPK:PSID) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PositiveID's Gross Margin % for the three months ended in Mar. 2018 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.228 / 0.42
=45.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


PositiveID COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PositiveID's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PositiveID (PositiveID) Business Description

Traded in Other Exchanges
N/A
Address
1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445
PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.
Executives
Ned L Siegel director 600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz director 1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein director 1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman other: Former 10% Owner
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K director 2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

PositiveID (PositiveID) Headlines

From GuruFocus

PositiveID's Chairman and CEO Addresses Stockholders

By Marketwired Marketwired 04-26-2018